Could Aduhelm Be Taken Off Market If CMS Proposal Stands? ‘Everything Is On The Table,’ Biogen Says

 
• By Brenda Sandburg
  
Aducanumab
Alzheimer's disease drug Aduhelm (aducanumab) faces new hurdle with CMS national coverage decision • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Scrip